Circio Holding ASA (”Circio” or ”the Company”) announced, on the 27th of May 2026, a research collaboration with AaviGen GmbH (”AaviGen”), a Heidelberg-based biotechnology company developing precision gene therapies for cardiac diseases. The collaboration aims to enable low-dose, high-precision AAV gene therapy for genetic and chronic heart conditions by combining circVec with AaviGen’s proprietary heart-targeted capsids, and will proceed in three stages: production of novel AAVs that combine AaviGen’s capsids with Circio’s circVec expression cassette, in vitro characterization, and in vivo validation of AAV biodistribution and gene expression profiles. No financial terms are disclosed.
Analyst Group’s View on the AaviGen Collaboration
The agreement engages with a layer of the AAV system that Circio’s external partnership network has not previously addressed: capsid engineering. The capsid is the outer protein shell that determines which cells an AAV vector reaches after injection, and engineering it for tissue specificity is one of the most active areas of AAV research today. While Circio’s big pharma CNS feasibility study uses a standard AAV format, the AaviGen agreement is the first to combine circVec with an externally developed, tissue-targeted capsid. The collaboration is anchored in heart, a tissue where circVec has delivered strong preclinical data to date, up to approx. 40x enhanced expression with circVec 3.2 versus conventional AAV.
AAV gene therapy is limited commercially by the high doses needed for therapeutic effect, which raise both safety risk and cost. The required dose depends on two factors: how much of the vector reaches the target cells, and how much protein each cell produces. AaviGen’s heart-targeted capsids improve the first; circVec, by stabilizing the RNA inside the cell, improves the second. Because the two act on different stages of the same problem, they can be combined without overlap, the synergy the collaboration is designed to test.
In summary, Analyst Group views the AaviGen collaboration as a strategically coherent extension of Circio’s delivery partnership network. The broader takeaway is the cadence and breadth of Circio’s 2026 partnership activity, with five collaborations announced within five months, spanning multiple delivery technologies and therapeutic contexts. Analyst Group considers this both a credible external validation signal, given that five technically independent counterparties have chosen circVec as the expression component for their own platforms, and a meaningful de-risking factor, as the commercial path is now distributed across multiple parallel programs rather than concentrated in any single agreement.
